New Gout Drug Gets FDA Panel Nod
Uloric, First New Gout Drug in 40 Years, Recommended for FDA Approval
WebMD News Archive
Nov. 24, 2008 -- Uloric should be the first new gout drug to be approved in
over 40 years, an FDA expert panel recommends.
Currently, allopurinol (trade name, Zyloprim) is the only FDA-approved drug
that prevents formation of the uric acid crystals that cause gout. However,
side effects -- including potentially fatal reactions -- limit the amount of
allopurinol that can be tolerated. Most gout patients do not receive fully
effective doses of allopurinol.
In clinical trials sponsored by Takeda, Uloric's manufacturer, an
80-milligram dose of Uloric worked better than allopurinol; a 40-milligram dose
worked at least as well as allopurinol.
Unlike allopurinol, very little Uloric is excreted through the urine, making
Uloric safe for patients with kidney problems. Gout patients with impaired
kidney function have to take very low doses of allopurinol, making the drug
even less effective for these patients.
In 2005, the FDA refused to approve Uloric because there were slightly more
deaths and heart problems in patients taking the drug than in patients taking
allopurinol. As people with gout problems already are at higher risk of heart disease, the FDA issued an
"approvable" letter, noting that Uloric could be approved if this
safety question were addressed.
Takeda then performed a large new phase 3 clinical trial that enrolled more
gout patients than the two previous phase 3 trials combined. The new study
found no more deaths and no more heart problems in patients taking Uloric than
in patients taking allopurinol.
Based on the safety and efficacy data, the FDA panel recommended by a 12-0
vote that the FDA approve Uloric at both the 40-milligram and 80-milligram
doses. Takeda suggests the higher dose is more effective in subjects with more
Takeda has offered to continue studying Uloric after FDA approval. A phase 4
clinical trial would compare Uloric to allopurinol for the reduction of gout
And because drugs with the same mechanism
of action as Uloric and allopurinol may affect theophylline bronchodilators, Takeda has
agreed to conduct a postmarketing phase 1 study of Uloric's interactions with
Gout occurs when blood levels of uric acid rise. At blood levels above 7
mg/dL -- and above 6 mg/dL in the extremities -- crystals can form that lodge
in the joints and other body tissues. These crystal deposits provoke an immune
response that results in extremely painful swelling and in inflammatory arthritis that can permanently
destroy the joints.